Overview

Bioavailability of Subcutaneous Dexmedetomidine

Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to investigate the pharmacokinetics of subcutaneously administered dexmedetomidine in healthy volunteers. The absolute bioavailability of subcutaneously administered dexmedetomidine will be calculated. In addition, the investigators will report the effects of subcutaneously administered dexmedetomidine on plasma catecholamine levels, vital signs such as systemic blood pressure, heart rate and sedation. The investigators will also monitor the local and systemic safety and tolerability of subcutaneously administered dexmedetomidine.
Phase:
Phase 4
Details
Lead Sponsor:
Turku University Hospital
Treatments:
Dexmedetomidine